Precision AQ - Investor Relations & External Communications is a premier investor relations firm, representing biotechnology companies across all market capitalizations and stages of development, and offering strategic and client-specific advisory services. For more information please visit our website at www.precisionaq.com
🚀 Thrilled to announce a $150 million Series C financing!
We are grateful to co-leads Frazier Life Sciences and Lightspeed Venture Partners, and all our new and existing investors. This funding will significantly advance our precision oncology pipeline, including key programs STX-478, STX-721 and STX-241. Discover how this supports our mission to push the boundaries of precision oncology https://bit.ly/4d36l6U
LENZ announces a $30M investment from Ridgeback Capital to further strengthen its Balance Sheet with an aim to make LNZ100 a potentially best-in-class therapeutic option for the treatment of presbyopia.
“We invest in innovative people and companies that help patients. LENZ is developing a medicine that can have a transformational impact on eyesight. This can benefit millions of people who live with the challenges of presbyopia, and we are excited to support the LENZ team in this effort,” said Dr. Wayne Holman, Chief Executive Officer and Founder of Ridgeback Capital.
Read full press release here: https://lnkd.in/gC8B39fJ
Congratulations to client Skyhawk Therapeutics on their announcement this morning of positive topline results from Parts A and B of their Phase 1 clinical trial of SKY-0515 as a potential treatment for Huntington's Disease!
Skyhawk Therapeutics Announces Positive Topline Results from Parts A and B of its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease, Reaching 72% Huntingtin mRNA Reduction
The Skyhawk team is delighted with the speed at which this study was conducted and thrilled to report such compelling results for SKY-0515. These topline data represent a crucial step forward for SKY-0515 and demonstrate the immense potential of the Skyhawk platform to target indications for which there are no approved disease modifying therapies.
Learn More: https://lnkd.in/eYBJAnUH#HuntingtonsDisease#DrugDevelopment#Skyhawk#SmallMoleculeRNA
Earlier this month at the Jefferies Global Healthcare Conference, Precision BioSciences, Inc. CFO Alex Kelly sat down with Precision AQ EVP & Managing Director, Hannah Deresiewicz, to discuss the company’s proprietary ARCUS® in vivo gene editing platform and pipeline with the aim of delivering lasting cures for patients with a range of genetic diseases where no adequate treatments exist.
Discover the key features and differentiating characteristics that may enable ARCUS nucleases to drive durable therapeutic outcomes in chronic hepatitis B (PBGENE-HBV), m3243 primary mitochondrial myopathy (PBGENE-PMM), Duchenne muscular dystrophy (PBGENE-DMD) and beyond in Precision AQ's "Access to the Best and Brightest" series!
Statements contained in this video by Precision Biosciences regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. A full description of risks and uncertainties can be found in Precision Biosciences filings with the Securities and Exchange Commission.
Congratulations to client argenx who announced the FDA approval of a new treatment for adults with chronic inflammatory demyelinating polyneuropathy (CIDP)!
Today we announced the FDA approval of a new treatment for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). This approval marks a key advancement in the understanding of rare, autoimmune diseases, and we are proud to deliver a new, innovative option for the #CIDP community. #TogetherWeDiscover Learn more: https://bit.ly/45D76Rl
CytomX Therapeutics CEO and Chairman Sean McCarthy sat down with Precision AQ EVP & Managing Director, Hannah Deresiewicz, at the Jefferies Global Healthcare Conference earlier this month to discuss the company’s differentiated Probody platform designed to localize the activity of potent anticancer biologics, including T-cell engagers, ADCs, and cytokines in the tumor microenvironment to increase the therapeutic index.
Learn more about CytomX’s pioneering work in the field of masked therapeutics and the Phase 1a data for its CX-904 program, partnered with #Amgen, which demonstrated a favorable safety profile and meaningful tumor reductions in pancreatic cancer, a very difficult to treat tumor type, in Precision AQ's "Access to the Best and Brightest" series!
Resolution Therapeutics is excited to host an R&D webinar with a live Q&A on Friday 28th June at 12.30 BST / 7.30 EDT!
The management team will be joined by expert hepatologist, Arun Sanyal, M.D., and will provide an in-depth update on the extended MATCH Phase 2 clinical study as well as discuss Resolution’s innovative macrophage cell therapy platform following the teams’ presentations at this year’s #EASL2024 Annual Congress.
Register now and submit your questions in advance of the R&D webinar using the following link: https://lnkd.in/ecTGYD-w
See you there!
#ESLD#Macrophage#CellTherapy
Congratulations to GeoVax Labs, Inc. on receiving the BARDA Project NextGen Award to conduct their Phase 2b clinical study evaluating the company's next-generation COVID-19 vaccine candidate, GEO-CM04S1.
Congratulations to client Spur Therapeutics on their exciting rebrand announcement! This marks the beginning of a thrilling new chapter for an exceptional team. We looking forward to seeing all that you will do.
Exciting announcement: Freeline is now Spur Therapeutics!
Our new name and branding reflects our dedication to advancing the practice of genetic medicine, moving toward a new generation of therapies that can change the course of disease progression—and change the course of people’s lives.
Check out our new website to learn more: www.spurtherapeutics.com
Read the press release: https://lnkd.in/gGZJpQrN